Chronic Periodontitis Clinical Trial
Official title:
Comparison of Clinical and Radiographic Parameters in the Application of Cross-linked Hyaluronic Acid 1.8% (Hyadent BG®) and Enamel Matrix Derivative (Emdogain®) in Periodontal Regeneration: A Randomized Clinical Trial
The aim of this study is to compare the effectiveness in periodontal regeneration of cross-linked hyaluronic acid at 1.8% (Hyadent BG®) with enamel matrix derivative (Emdogain®) in periodontal bone defects evaluating their clinical and radiographic variables.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 2022 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Periodontitis stage II or III, grade A or B: based on the "Consensus report of workgroup of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions" Tonetti 2017. Clinical attachment loss of 3-5mm, radiographic bone loss to the middle third, loss of teeth =4 due to periodontitis, probing depth = 6 mm. 2. At least, 20 teeth in the mouth. 3. Plaque Index (PI) < 1, following initial nonsurgical periodontal therapy and hygiene instructions. 4. At least one interproximal 2, 3-wall bone defect with moderate to deep intrabony defects (=3mm) on the radiographs, and clinical probing depths (PD) >5mm using William's graduated periodontal probe on premolars or molars following initial nonsurgical periodontal therapy. 5. Absence of caries or overflowing restorations and periapical injuries of the target tooth. 6. Non-smokers. 7. Absence of systemic disease. 8. Negative history for pregnancy 9. No relevant medical history that contraindicate periodontal surgery. 10. All participants signed an inform consent form. 11. The participant is female or male adult of = 18 years. The sample in sex will be compensated. 12. The participant is willing and able to return to the treatments and evaluations programmed throughout this clinical study. Exclusion Criteria: 1. The participant is pregnant or lactating or plans to become pregnant within the next 6 months. 2. Heavy smoker (>10 cigarettes/day). 3. The participant takes> 4 U of alcohol / day. 4. The participant has a chronic illness or decreased mental capacity which would mitigate the ability to comply with the protocol. 5. Taking drugs that could alter the participant's response in healing or with oral concomitant manifestations that, in the opinion of the investigator, could interfere with the assessment of safety or efficacy. 6. Participants with systemic diseases that interfere with treatment such as, Diabetes mellitus, or rheumatoid arthritis. 7. Allergies to drug compounds. 8. The participant has been treated with antibiotics within 3 months before starting the study or has any other systemic condition that requires antibiotic coverage for routine periodontal procedures (eg, heart disease, prosthetic joints, etc.). 9. Participants should not have received periodontal tretment within the 6-month period prior to study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Valencia | Regedent AG, Zürich |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical measure: Clinical attachment loss (CAL). Changes will be assessed at 3 time points. | It is defined as the distance in millimeters between CEJ and the end of the periodontal pocket. The calculation of the depth of the pocket + gingival recession or pocket depth - gingival hyperplasia will be carried out. | 1. Baseline, 2. Reevaluation (60 days after root debridement), 3. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Radiographic measure: Cemento-enamel junction (A1) | • The cemento-enamel junction (CEJ)of the tooth involved in the intrabony defect. | 1. Baseline, 2. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Radiographic measure: B1 | The most coronal position of the alveolar bone crest of the intrabony defect when it touches the root surface of the adjacent tooth before treatment (the top of the crest). | 1. Baseline, 2. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Radiographic measure: D1 | The most apical extension of the intrabony destruction where the periodontal ligament space still retained its normal width before treatment (the bottom of the defect). | 1. Baseline, 2. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Clinical measure: Probing pocket depth (PPD). Changes will be assessed at 3 time points. | The probing depth will be measured in six areas (disto-buccal, mediate-vestibular, mesio-buccal, disto-palatal, mid-palatal, and mesio-palatal) of each tooth with a Williams PQ-OW 208 396 probe. It will be use with a pressure of 20 grams that is equivalent to the pressure of dropping the weight of the probe without exerting additional pressure. | 1. Baseline, 2. Reevaluation (60 days after Scale and root planing), 3. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Clinical measure: Gingival recession (GR). Changes will be assessed at 3 time points. | The "Full mouth bleeding score" (FMBS) will be calculated based on scores of 0 (no bleeding) or 1 (bleeding) after probing depths are checked. The usual thing is to measure 4 points for each tooth, but we have modified the index and we value 6 points per tooth (disto-buccal, mid-buccal, mesio-buccal, disto-palatal, mid-palatal and mesio-palatal). We consider that the score is 1 when we see a red dot in the% bleeding diagram of the periodontogram and 0 when we see the blank box. |
1. Baseline, 2. Reevaluation (60 days after Scale and root planing), 3. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Clinical measure: Tooth mobility (TM) Miller (1950). Changes will be assessed at 3 time points. | Class I: Mobility up to 1 mm in the horizontal direction. Class II: Mobility greater than 1 mm in the horizontal direction. Class III: Excessive movement in both horizontal and vertical directions. |
1. Baseline, 2. Reevaluation (60 days after Scale and root planing), 3. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Clinical measure: Furcation involvement: Hamp (1975). Changes will be assessed at 3 time points. | The plaque will be quantified as follows: Score 0 = no plaque Score 1 = A film of plaque adhered to the free gingival margin and the adjacent area of the tooth. The plaque can be seen in situ only after the application of a plaque revealer or by using the probe on the surface of the tooth. Score 2 = moderate accumulation of soft deposits in the pocket, tooth or gingival margin, which can be seen with our eyes. Puntuación 3 = Abundance of soft material inside the bag and / or on the tooth and the gingival margin. The evaluation will be carried out in 4 points per tooth (disto-buccal, mesio-buccal, disto-palatal, mesio-palatal). |
1. Baseline, 2. Reevaluation (60 days after Scale and root planing), 3. Second reevaluation (180 days after Periodontal regenerative surgery). | |
Secondary | Clinical measure: Plaque Index (Sillness y Löe 1964). Changes will be assessed at 3 time points. | The plaque will be quantified as follows: Score 0 = no plaque Score 1 = A film of plaque adhered to the free gingival margin and the adjacent area of the tooth. The plaque can be seen in situ only after the application of a plaque revealer or by using the probe on the surface of the tooth. Score 2 = moderate accumulation of soft deposits in the pocket, tooth or gingival margin, which can be seen with our eyes. Puntuación 3 = Abundance of soft material inside the bag and / or on the tooth and the gingival margin. The evaluation will be carried out in 4 points per tooth (disto-buccal, mesio-buccal, disto-palatal, mesio-palatal). |
1. Baseline, 2. Reevaluation (60 days after Scale and root planing), 3. Second reevaluation (180 days after Periodontal regenerative surgery). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06400069 -
Role of NLRP6 in Chronic Periodontitis
|
||
Completed |
NCT05231096 -
Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis
|
N/A | |
Completed |
NCT03203746 -
Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Completed |
NCT02516111 -
Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment
|
Phase 2/Phase 3 | |
Completed |
NCT02174146 -
Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy
|
N/A | |
Terminated |
NCT02568163 -
Influence of Stress on Non Surgical Periodontal Treatment
|
N/A | |
Completed |
NCT02430519 -
Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects
|
N/A | |
Completed |
NCT01438333 -
Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection
|
N/A | |
Completed |
NCT01233765 -
Analysis of Neutrophil Response in Chronic Periodontitis
|
N/A | |
Completed |
NCT02218515 -
Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft
|
Phase 4 | |
Completed |
NCT02197260 -
Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing
|
Phase 4 | |
Not yet recruiting |
NCT03270280 -
Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis
|
Phase 2 | |
Not yet recruiting |
NCT04026828 -
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
|
||
Completed |
NCT04697199 -
The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis
|
Phase 1 | |
Completed |
NCT04643288 -
Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects
|
N/A | |
Completed |
NCT03039244 -
Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers
|
N/A | |
Completed |
NCT02851823 -
Combined Use of Er:YAG and Nd:YAG Laser
|
N/A | |
Completed |
NCT03874390 -
Effects of Ozone Therapy on Clinical Parameters and Inflammatory Cytokines in Chronic Periodontitis Patients
|
N/A | |
Completed |
NCT02518152 -
Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis
|
Phase 2/Phase 3 |